Bayer CropScience Limited

Report azionario BSE:506285

Capitalizzazione di mercato: ₹207.1b

Bayer CropScience Crescita futura

Criteri Future verificati 2/6

Bayer CropScience prevede che gli utili e i ricavi cresceranno rispettivamente di 10.9% e 9.2% all'anno. Si prevede che l'EPS crescerà di 11.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 27.8% in 3 anni.

Informazioni chiave

10.9%

Tasso di crescita degli utili

11.90%

Tasso di crescita dell'EPS

Chemicals crescita degli utili20.5%
Tasso di crescita dei ricavi9.2%
Rendimento futuro del capitale proprio27.83%
Copertura analitica

Good

Ultimo aggiornamento10 Apr 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento dell'analisi • May 01

506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook

Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.
Aggiornamento dell'analisi • Apr 17

506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook

The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.
Aggiornamento dell'analisi • Apr 02

506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
Aggiornamento dell'analisi • Mar 19

506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook

Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).
Aggiornamento dell'analisi • Mar 04

506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook

Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
Aggiornamento dell'analisi • Feb 17

506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook

Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
Aggiornamento dell'analisi • Feb 03

506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.
Aggiornamento dell'analisi • Jan 20

506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.
Aggiornamento dell'analisi • Jan 05

506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.
Aggiornamento dell'analisi • Dec 21

506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year

Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.
Aggiornamento dell'analisi • Dec 07

506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025

Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.
Aggiornamento dell'analisi • Nov 23

506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025

Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.
User avatar
Nuova analisi • May 18

Seeds, Traits And Biofuels Will Unlock New Value Pools

Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.

Previsioni di crescita degli utili e dei ricavi

BSE:506285 - Stime future degli analisti e dati finanziari passati (INR Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/202868,6988,4827,402N/A8
3/31/202762,4927,4956,348N/A8
3/31/202656,9986,7456,730N/A8
12/31/202556,2066,704N/AN/AN/A
9/30/202555,7186,0892,5703,127N/A
6/30/202557,5665,925N/AN/AN/A
3/31/202554,7345,6802,2112,620N/A
12/31/202452,1725,207N/AN/AN/A
9/30/202451,1525,79610,25210,753N/A
6/30/202449,9486,662N/AN/AN/A
3/31/202451,0627,4059,0599,516N/A
12/31/202352,9428,030N/AN/AN/A
9/30/202353,7728,4444,0204,478N/A
6/30/202352,1197,841N/AN/AN/A
3/31/202351,3977,5825,3206,093N/A
12/31/202251,2057,524N/AN/AN/A
9/30/202250,7277,0273,0703,842N/A
6/30/202249,8596,942N/AN/AN/A
3/31/202247,3446,4531,6012,155N/A
12/31/202145,0485,545N/AN/AN/A
9/30/202144,3294,246268698N/A
6/30/202144,4944,951N/AN/AN/A
3/31/202142,6134,9316,4476,867N/A
12/31/202039,9134,627N/AN/AN/A
9/30/202039,2716,45711,55312,052N/A
6/30/202038,9185,909N/AN/AN/A
3/31/202036,0944,7456,2466,659N/A
12/31/201929,2942,864N/AN/AN/A
9/30/201928,5052,116N/A2,432N/A
6/30/201925,2561,497N/AN/AN/A
3/31/201931,7543,371N/A4,328N/A
12/31/201828,6393,045N/AN/AN/A
9/30/201827,2262,877N/AN/AN/A
6/30/201828,5053,356N/AN/AN/A
3/31/201827,1673,001N/A1,214N/A
12/31/201726,3752,769N/AN/AN/A
9/30/201728,2033,030N/AN/AN/A
6/30/201726,7962,715N/AN/AN/A
3/31/201728,1532,910N/A1,573N/A
12/31/201640,1053,323N/AN/AN/A
9/30/201632,0303,342N/AN/AN/A
6/30/201638,0273,215N/AN/AN/A
3/31/201627,8383,151N/A2,065N/A
12/31/201537,9193,278N/AN/AN/A
9/30/201538,5693,554N/AN/AN/A
6/30/201539,2223,814N/AN/AN/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 506285 ( 10.9% all'anno) è superiore al tasso di risparmio ( 6.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 506285 ( 10.9% all'anno) cresceranno più lentamente rispetto al mercato Indian ( 16.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 506285 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 506285 ( 9.2% all'anno) crescerà più lentamente rispetto al mercato Indian ( 11% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 506285 ( 9.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 506285 sarà elevato tra 3 anni ( 27.8 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/09 20:26
Prezzo dell'azione a fine giornata2026/05/08 00:00
Utili2025/12/31
Utili annuali2025/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bayer CropScience Limited è coperta da 26 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null null360 ONE Capital Market Private Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Himanshu BinaniAnand Rathi Shares and Stock Brokers Limited